Retrospective study on CT-guided iodine-125 radioactive seed implantation for non–small cell lung cancer patients with severe pulmonary dysfunction: Analysis of efficacy and safety
Brachytherapy · 2026
DOI: 10.1016/j.brachy.2026.07.170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Ziyu Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Medicine, Beijing Anzhen Nanchong Hospital, Capital Medical University and Nanchong Central Hospital, Nanchong, China. E…. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Brachytherapy. Die Arbeit nennt 27 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: To evaluate the efficacy and safety of CT-guided iodine-125 (¹²⁵I) radioactive seed implantation in non-small cell lung cancer (NSCLC) patients with severe pulmonary dysfunction. METHODS: A retrospective analysis was performed on 56 NSCLC patients with severe pulmonary dysfunction who underwent ¹²⁵I seed implantation at Nanchong Central Hospital from January 2020 to December 2024. Short-term efficacy, survival outcomes, pulmonary function, Karnofsky Performance Status (KPS), and adverse events were observed. Prognostic factors were analyzed by Cox regression. RESULTS: The 1-year objective response rate (ORR) was 60.7% and disease control rate (DCR) was 67.9%. The median overall survival (OS) was 18.0 months, and median progression-free survival (PFS) was 13.0 months. Multivariate analysis showed that tumor maximum diameter, D90 ≥120 Gy, and postoperative systemic therapy were independent prognostic factors for OS and PFS. The most common adverse event was pneumothorax requiring drainage (25.0%), with no grade ≥3 radiation pneumonitis or treatment-related deaths. Pulmonary function and KPS scores showed no significant deterioration within 12 months postoperatively. CONCLUSION: CT-guided ¹²⁵I seed implantation is effective and safe for NSCLC patients with severe pulmonary dysfunction, with favorable tumor control and survival while preserving pulmonary function without significant decline within 12 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interventional Medicine, Beijing Anzhen Nanchong Hospital, Capital Medical University and Nanchong Central Hospital, Nanchong, China. Electronic address: 18281796570@163.com.
- Department of Interventional Radiology, Sichuan Provincial People's Hospital, Chengdu, China.
- Department of Interventional Medicine, Beijing Anzhen Nanchong Hospital, Capital Medical University and Nanchong Central Hospital, Nanchong, China.
- Department of Respiratory and Critical Care Medicine, Nanjiang County People's Hospital, Bazhong, China.
Zitieren
APA
Tang, Z., Li, J., Qiu, S., Liao, Y., Hu, H., Gou, B., Pu, J., Wei, X., & Li, C. (2026). Retrospective study on CT-guided iodine-125 radioactive seed implantation for non–small cell lung cancer patients with severe pulmonary dysfunction: Analysis of efficacy and safety. Brachytherapy. https://doi.org/10.1016/j.brachy.2026.07.170
Vancouver
Tang Z, Li J, Qiu S, Liao Y, Hu H, Gou B, et al. Retrospective study on CT-guided iodine-125 radioactive seed implantation for non–small cell lung cancer patients with severe pulmonary dysfunction: Analysis of efficacy and safety. Brachytherapy. 2026. doi:10.1016/j.brachy.2026.07.170
BibTeX
@article{Tang2026,
author = {Tang, Ziyu and Li, Jinze and Qiu, Shixiang and Liao, Yunguo and Hu, Hong and Gou, Bolin and Pu, Jiaqi and Wei, Xin and Li, Chao},
title = {Retrospective study on CT-guided iodine-125 radioactive seed implantation for non–small cell lung cancer patients with severe pulmonary dysfunction: Analysis of efficacy and safety},
journal = {Brachytherapy},
year = {2026},
doi = {10.1016/j.brachy.2026.07.170}
}
EUVIMED